Compare LCID & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCID | TARS |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.6B |
| IPO Year | 2020 | 2020 |
| Metric | LCID | TARS |
|---|---|---|
| Price | $4.19 | $75.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | $7.94 | ★ $99.50 |
| AVG Volume (30 Days) | ★ 9.3M | 615.8K |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $595,271,000.00 | $451,360,000.00 |
| Revenue This Year | $20.85 | $59.75 |
| Revenue Next Year | $121.41 | $28.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $2.37 | $53.89 |
| 52 Week High | $25.22 | $91.53 |
| Indicator | LCID | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 39.89 | 56.70 |
| Support Level | $3.99 | $60.95 |
| Resistance Level | $4.55 | $79.10 |
| Average True Range (ATR) | 0.21 | 2.35 |
| MACD | 0.07 | -0.51 |
| Stochastic Oscillator | 44.60 | 80.38 |
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It offers its own geographically distributed retail and service locations through direct-to-consumer online and retail sales. It also boasts a product roadmap of future vehicle programs and technologies. It focuses on in-house hardware and software innovation, vertical integration, and a clean-sheet approach to engineering and design, which led to the development of the Lucid Air. The Lucid Air is a luxury sedan that redefines both the luxury car segment and the EV space. Its geographic segments include North America, the Middle East, and Other International.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.